1Y Close · As of Aug 26, 2026
SK Biopharmaceuticals operates in the Professional Services sector.
Legal name: SK biopharmaceuticals Co., Ltd.
In fiscal year 2025, SK Biopharmaceuticals (326030) reported revenue of 706.7 billion KRW, up 29.1% from 547.6 billion KRW a year earlier.
Operating profit was 203.9 billion KRW and net income was 253.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 7.17 trillion KRW, with a P/B of 8.68.
These figures can be verified in the DART filing (receipt no. 20260318000773).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 706.7B | 203.9B | 253.3B |
| 2024 | 547.6B | 96.3B | 227.0B |
| 2023 | 354.9B | -37.5B | -35.4B |
Recent Filings
Large Group Status Disclosure (Quarterly Disclosure Individual)
Corporate Briefing (IR) (Informational Disclosure)
투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim 등)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-27 | Large Group Status Disclosure (Quarterly Disclosure Individual) |
| 2026-08-26 | Corporate Briefing (IR) (Informational Disclosure) |
| 2026-08-26 | 투자판단관련주요경영사항 (뇌전증 신약 후보 물질 Opakalim 등) |
| 2026-08-18 | Sales/Supply Contract |
| 2026-08-14 | Semi-Annual Report (2026.06) |